GlassScriptPhysician profile
Haleh Safavi
NPI 1427210764
$4,053.33
in general payments reported to CMS, 2019-2025
36 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $281 · 2021: $467 · 2022: $624 · 2023: $392 · 2024: $592 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $561.83 | 2019-2025 | Spravato |
| Abbvie INC. | $513.44 | 2020-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $488.88 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $301.31 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $266.67 | 2019-2022 | |
| Lilly USA, LLC | $244.94 | 2019-2025 | Mounjaro, Trulicity, Kisunla |
| Abbott Laboratories | $226.69 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $164.56 | 2019-2024 | Gattex |
| Glaxosmithkline, LLC. | $164.37 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $154.38 | 2019-2025 | Airsupra, Lokelma, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.96 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.68 | 2019-2022 | |
| Dexcom, INC. | $70.00 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $65.78 | 2019-2020 | |
| Shire North American Group INC | $60.17 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $56.38 | 2020-2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $55.19 | 2019 | |
| Abiomed | $49.06 | 2023 | Impella |
| Astellas Pharma US INC | $47.94 | 2021 | |
| Biogen, INC. | $43.07 | 2024-2025 | Leqembi |
| Sanofi-Aventis U.S. LLC | $42.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.88 | 2019-2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $28.79 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $28.64 | 2019-2022 | |
| Allergan, INC. | $24.00 | 2020 | |
| Gilead Sciences, INC. | $23.97 | 2025 | |
| Corcept Therapeutics | $22.84 | 2025 | Korlym |
| Shield Therapeutics INC | $21.31 | 2022 | |
| Seqirus USA INC | $19.24 | 2022 | |
| Medtronic Minimed, INC. | $17.83 | 2019 | |
| Radius Health, INC. | $16.86 | 2023 | Tymlos |
| Phathom Pharmaceuticals, INC. | $15.67 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $15.51 | 2022 | |
| Cequr Corporation | $15.12 | 2022 | |
| Lundbeck LLC | $14.88 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haleh Safavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.